Results 131 to 140 of about 3,411,532 (259)
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens +8 more
wiley +1 more source
Benefits of a non-traditional science communication and internship experience based on research from the National Science Foundation Research Traineeship at a Research Intensive University. [PDF]
Dasgupta S +4 more
europepmc +1 more source
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi +6 more
wiley +1 more source
Conservation Science at Korea’s National Museums
Heisun Yu
doaj +1 more source
Technology Assessment in Australia’s National Science Agency
Peta Ashworth
doaj +1 more source
Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang +4 more
wiley +1 more source
The High-Value Nutrition National Science Challenge programme: facilitating collaboration between academia and the food and beverage industry to develop healthier foods. [PDF]
Mithen R +5 more
europepmc +1 more source
Engaging rural Australian communities in National Science Week helps increase visibility for women researchers. [PDF]
Hardy MC +2 more
europepmc +1 more source
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley +1 more source

